Research & Clinical Trials
Current & Past Trials on Parkinson's Disease
Ongoing Research & Clinical Trials
Parkinson's Outcomes Project
Started in 2009, the Parkinson’s Outcomes Project is the largest-ever clinical study of Parkinson’s disease with more than 13,000 participants in five countries. Through this groundbreaking initiative, Parkinson’s Foundation Centers of Excellence track and monitor their care of people with Parkinson’s over time.
Did you know that people with Parkinson's disease (PD) have a higher risk of fractures? Help us find a solution. The TOPAZ study will test if a medicine called zoledronate can prevent fractures in people with PD. A team of doctors who are experts in bone health and PD are leading the study. The use of zoledronate in this study is investigational.
Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
Patients described themselves in home diaries every 30 minutes during waking hours for 3 consecutive days prior to Baseline, Weeks 8, 12, 16, and 20. Unified Parkinson's Disease (PD) Rating Scale (UPDRS) is a standardized assessment of the symptoms and signs of PD. Part II assesses Activities of Daily Living (ADL) based on 13 items, such as speech, hygiene, and falling. Participants receive a score of 0-4 points per item, with a higher score indicating more severe symptoms. Range of possible total scores, 0 to 52. ON state is when medication is providing benefits to mobility, slowness, and stiffness. OFF state is when medication has worn off and is no longer providing benefits with regard to stiffness, slowness, and tremor.
The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.